| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4755384
Max Phase: Preclinical
Molecular Formula: C16H15N3O5S2
Molecular Weight: 393.45
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: O=C(Nc1c2c(cc3c1OCC3)OCC2)NS(=O)(=O)/C=C/c1nccs1
Standard InChI: InChI=1S/C16H15N3O5S2/c20-16(19-26(21,22)8-3-13-17-4-7-25-13)18-14-11-2-6-23-12(11)9-10-1-5-24-15(10)14/h3-4,7-9H,1-2,5-6H2,(H2,18,19,20)/b8-3+
Standard InChI Key: NBWOPCWUHNAHIN-FPYGCLRLSA-N
Associated Targets(Human)
NACHT, LRR and PYD domains-containing protein 3 908 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 393.45 | Molecular Weight (Monoisotopic): 393.0453 | AlogP: 2.14 | #Rotatable Bonds: 4 |
| Polar Surface Area: 106.62 | Molecular Species: ACID | HBA: 7 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 3.66 | CX Basic pKa: 2.48 | CX LogP: 1.15 | CX LogD: 0.40 |
| Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.82 | Np Likeness Score: -0.95 |
References
| 1. Agarwal S,Pethani JP,Shah HA,Vyas V,Sasane S,Bhavsar H,Bandyopadhyay D,Giri P,Viswanathan K,Jain MR,Sharma R. (2020) Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor., 30 (21.0): [PMID:32980515] [10.1016/j.bmcl.2020.127571] |
Source
Source(1):